The Department of Health – Abu Dhabi (DoH), the Abu Dhabi Investment Office (ADIO), and GSK, a global leader in biopharmaceuticals, have joined forces to establish a Multi-Omics Research Institute in Abu Dhabi. This partnership was formalized with a Memorandum of Understanding (MoU) signed during the Abu Dhabi Global Health Week (ADGHW). The initiative aims to accelerate research in oncology-focused genomic science and precision medicine, contributing to improved outcomes for cancer patients and enhancing global representation in genomic research.

Multi-omics research involves studying various biological molecules, such as genes, RNA, proteins, and metabolites, to understand their interactions within living organisms. This comprehensive approach allows scientists to gain deeper insights into biological processes, ultimately improving health outcomes and disease management.

The MoU signing included notable figures such as H.E. Mansoor Al Mansoori, Chairman of DoH, H.E. Ahmed Jasim Al Zaabi, Chairman of the Abu Dhabi Department of Economic Development (ADDED), and Sir Jonathan Symonds, Chairman of GSK. Also present were H.E. Dr. Noura Al Ghaithi, Undersecretary of DoH, H.E. Badr Al-Olama, Director General of ADIO, and Hesham A. Abdullah, Senior Vice President at GSK.

According to UAE News 24/7, H.E. Dr. Noura Khamis Al Ghaithi said that this initiative aligns with the vision to create a leading healthcare system, utilizing advanced technologies and scientific research to enhance precision medicine. She noted that the Multi-Omics Institute would generate high-quality omics data, fostering innovative healthcare solutions and reinforcing Abu Dhabi’s role as a premier destination for life sciences.

Leveraging Abu Dhabi’s advanced biotechnology and genomics infrastructure, this multinational initiative aims to embed early-stage discovery research within the UAE. It seeks to foster scientific innovation in oncology and diversify genomic research to ultimately benefit cancer patients.

H.E. Badr Al-Olama remarked that establishing the Multi-Omics Research Institute is a significant milestone for Abu Dhabi, marking its evolution into a global hub for health innovation. He stated that embedding discovery-stage science within the local ecosystem supports critical oncology research and strengthens the emirate’s leadership in biotechnology and precision medicine.

Dr. Hesham Abdullah highlighted the importance of this MoU in enhancing translational research capabilities and accelerating oncology drug discovery in the Middle East. He noted that public-private collaborations are vital for improving the understanding of disease biology and advancing treatment options for cancer patients both locally and globally.

ADGHW serves as a key government initiative by DoH, focusing on innovation and collaboration under the theme “Towards Longevity: Redefining Health and Well-being.” The event emphasizes community-driven health initiatives, with a proactive approach centered around preventive, personalized, and holistic care, guided by four core themes: Longevity and Precision Health, Health System Resilience & Sustainability, Digital Health & AI, and Investment in Life Sciences.